Carolina Chávez

Jan 7, 2025 | science.org | Dana M. Cairns |Carolina Chávez |Kelly Lin |Alexis Malveaux |Quen Cheng |Alexander Hoffmann | +2 more

Research ArticleINNATE IMMUNITY Access the full articleView all access options to continue reading this article. Supplementary MaterialsMDAR Reproducibility ChecklistREFERENCES AND NOTES1K. M. Sheu, A. Hoffmann, Functional hallmarks of healthy macrophage responses: Their regulatory basis and disease relevance. Annu. Rev. Immunol. 40, 295–321 (2022). 2M. G. Netea, J. Domínguez-Andrés, L. B. Barreiro, T. Chavakis, M. Divangahi, E. Fuchs, L. A. B. Joosten, J. W. M. van der Meer, M. M. Mhlanga, W. J. M. Mulder, N. P. Riksen, A.

Jan 7, 2025 | sciencemag.org | Dana M. Cairns |Carolina Chávez |Kelly Lin |Alexis Malveaux

Published In Science SignalingVolume 18 | Issue 868January 2025Article versionsSubmission historyReceived: 27 February 2024Accepted: 4 December 2024PermissionsRequest permissions for this article. AcknowledgmentsWe thank S. Smale for making ATAC-seq data from IRF3-deficient cells available in advance of publication. We acknowledge the expert evaluation of our statistical analyses by S.

Aug 9, 2024 | ruemag.com | Carolina Chávez

The story of this Newhall, California,1940s Tudor goes back a generation. “The home was purchased by our client’s parents years ago when they first moved to California,” designer Carolina Chavez tells us. “She cherished spending her childhood in the home with her siblings as it served as a gathering place for both immediate and extended family. She has since moved back, as she inherited the home after her parents passed away.

May 8, 2024 | nature.com | Richard Everson |Willy Hugo |Lu O. Sun |Joseph K. Antonios |Melissa Bu |Sara Khattab | +9 more

In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary endpoints were to assess the most effective combination of vaccine and adjuvant in order to enhance the immune potency, along with safety. The combination of ATL-DC vaccination and TLR agonist was safe and found to enhance systemic immune responses, as indicated by increased interferon gene expression and changes in immune cell activation. Specifically, PD-1 expression increases on CD4+ T-cells, while CD38 and CD39 expression are reduced on CD8+ T cells, alongside an increase in monocytes. Poly-ICLC treatment amplifies the induction of interferon-induced genes in monocytes and T lymphocytes. Patients that exhibit higher interferon response gene expression demonstrate prolonged survival and delayed disease progression. These findings suggest that combining ATL-DC with poly-ICLC can induce a polarized interferon response in circulating monocytes and CD8+ T cells, which may represent an important blood biomarker for immunotherapy in this patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01204684. Autologous tumor lysate (ATL) dendritic cell (DC) vaccination can induce local and systemic anti-tumor immune responses in malignant glioma patients. In this randomized phase II clinical trial, the authors evaluate the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to ATL-DC vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas.